805PA phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. (23rd October 2018) - Fizazi, K; Hussain, M; Saad, F; Shore, N; De Giorgi, U; Efstathiou, E; Ferreira, U; Ivashchenko, P; Madziarska, K; Al-Adhami, M; Modelska, K; Phung, D; et al.